Aprea strengthens its board
Stockholm, Sweden – January 20, 2014. Aprea AB, a Karolinska Development portfolio company, announces that Bernd R. Seizinger has been elected as a new member of the board. Bernd R. Seizinger, M.D., Ph.D., is Chairman of Opsona Therapeutics Ltd. and former Vice President, Oncology Drug Discovery at Bristol-Myers Squibb, Associate Professor of Neuroscience at Harvard Medical School and Associate Geneticist and Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital in Boston, MA, USA.
“We are pleased to welcome Dr. Seizinger to the board”, says Torbjörn Bjerke, Chairman of Aprea AB. “His extensive research and clinical development experience within oncology from the pharmaceutical and biotechnology industries will be a great benefit to the company as we move forward.”
As biotech and pharma senior executive, Dr. Seizinger has held a number of positions such as President & CEO of oncology drug discovery and clinical development company GPC Biotech (Munich, Boston, Princeton, Houston), Vice-President Oncology Drug Discovery at Bristol-Myers Squibb (Princeton), Executive Vice President and Chief Scientific Officer at Genome Therapeutics (Boston), as well as Executive Chairman/Interim CEO at Opsona Ltd. (Dublin). In addition to his current Board memberships at Opsona Ltd., Agennix AG, and TriMod Ltd., Dr. Seizinger previously held Board memberships at Altana Pharma AG, Santhera Pharmaceuticals, BioXell Spa, and Cytovia Inc.
Dr. Seizinger has authored more than 100 publications and has been the recipient of numerous scientific awards, including the Otto-Hahn-Medal of the Max-Planck-Society, the Wilson S. Stone Award for Cancer Research (U.S), and the von Recklinghausen Award by the U.S. National Neurofibromatosis Foundation.
For further information, please contact:
Ulf Björklund, CEO
Phone: +46 (0)8 50884504
TO THE EDITORS
Aprea AB is a Swedish biotech company focusing on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. The main owner of Aprea is KDev Investments AB, part of Karolinska Development AB (publ). The other main owners are Östersjöstiftelsen, Praktikerinvest and KD Co-Investment Fund KB. For more information, please visit www.aprea.com
APR-246 has been developed based on results from researchers at Karolinska Institutet, and has been shown to reactivate the non-functional tumor suppressor protein p53 and induce programmed cell death in many human cancer cells. In preclinical studies APR-246 has demonstrated unique pharmacological properties as compared to conventional chemotherapy, by being effective also in cancer cells with p53 mutations and by preferentially targeting tumor cells over normal cells. A clinical phase I/II study on hematological malignancies and prostate cancer with APR-246 has been completed with promising results. APR-246 had a good safety profile and both biological and clinical responses were observed. A Phase II Proof of Concept study in ovarian cancer patients carrying mutant p53 is currently being prepared.